For the quarter ending 2025-12-31, ENTA had $5,139K increase in cash & cash equivalents over the period. -$11,842K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Revenue From Contract With Customer Excluding Assessed Tax | 18,615 | 65,324 | - |
| License | - | 0 | - |
| Total revenue | 18,615 | 65,324 | - |
| Research And Development Expense | 4,921 | - | - |
| Research and development-Virology | 4,921 | 60,547 | - |
| Research and development-Immunology | 14,203 | 34,666 | - |
| Research and development-Other Programs | 1,735 | 11,527 | - |
| General and administrative | 9,009 | 43,933 | - |
| Loss from operations | -11,253 | -85,349 | - |
| Interest expense | 3,083 | 7,681 | - |
| Interest and investment income, net | 2,422 | 9,442 | - |
| Change in fair value of series 1 nonconvertible preferred stock | - | 39 | - |
| Total other (expense) income, net | -661 | 1,800 | - |
| Loss before income taxes | -11,914 | -83,549 | - |
| Income tax (expense) benefit | 24 | -1,660 | - |
| Net loss | -11,938 | -18,700 | -63,189 |
| Stock-based compensation expense | 3,810 | 4,034 | 14,531 |
| Depreciation and amortization expense | 1,230 | 1,284 | 3,302 |
| Non-cash interest associated with the sale of future royalties | 696 | -630 | - |
| Non-cash royalty revenue | 1,879 | -1,737 | 2,020 |
| Premium paid on marketable securities | 756 | 0 | - |
| Amortization of premiums on marketable securities | -20 | 958 | -1,461 |
| Loss on disposal of property and equipment | 0 | 0 | -6 |
| Change in fair value of series 1 nonconvertible preferred stock | - | 39 | - |
| Accounts receivable | 1,611 | -1,451 | 1,687 |
| Prepaid expenses and other current assets | -4,248 | -1,650 | -2,173 |
| Non-cash interest associated with the sale of future royalties | - | - | -1,399 |
| Income tax receivable | 0 | -24 | -31,975 |
| Operating lease, right-of-use assets | -546 | -701 | -3,607 |
| Other long-term assets | 1 | -2 | 0 |
| Accounts payable | -63 | -723 | -588 |
| Accrued expenses | -5,176 | 2,418 | -2,360 |
| Operating lease liabilities | -834 | -147 | 1,384 |
| Other long-term liabilities | 9 | 8 | 21 |
| Net cash used in operating activities | -11,699 | -6,489 | -12,783 |
| Purchase of marketable securities | 148,624 | 68,621 | 141,008 |
| Proceeds from maturities and sale of marketable securities | 101,469 | 72,375 | 190,497 |
| Purchase of property and equipment | 143 | 1,458 | 11,438 |
| Net cash (used in) provided by investing activities | -47,298 | 2,296 | 38,051 |
| Proceeds from the sale of future royalties | - | 0 | - |
| Proceeds from october 2025 public offering, net of issuance costs of 4,802 | 69,948 | - | - |
| Payments for debt issuance costs | - | 0 | - |
| Payments on royalty sale liability, net of imputed interest | 5,856 | 8,362 | 18,124 |
| Payments for settlement of share-based awards | 97 | 10 | 267 |
| Proceeds from the exercise of stock options | 141 | 51 | 94 |
| Net cash provided by (used) in financing activities | 64,136 | -8,321 | -18,297 |
| Net increase in cash, cash equivalents and restricted cash | 5,139 | -12,514 | 6,971 |
| Cash and cash equivalents at beginning of period | 35,658 | 41,201 | - |
| Cash and cash equivalents at end of period | 40,797 | 35,658 | - |
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)